La sclérodermie (SSc) est une maladie rare affectant les personnes génétiquement prédisposées d’une réponse immunitaire défectueuse. Malgré les derniers avancements et développements dans le domaine, l’étiologie et la pathogénèse de la maladie demeurent peu comprises. Par ailleurs, il y a un ralentissement dans la compréhension de cette maladie à cause du manque de modèle animal représentatif de la SSc humaine. Malgré plusieurs lacunes, les souris traitées avec la bléomycine ou portant des modifications génétiques (TSK-1) sont très utilisées dans les études précliniques de la SSc mais elles ne présentent pas toutes les caractéristiques de cette maladie. Pour contribuer à la recherche sur la SSc, la stagiaire postdoctorale Dre Heena Mehta a développé dans le laboratoire du Dre Sarfati en collaboration avec le Dr Senécal, un modèle de souris expérimental induit par l’immunisation de cellules dendritiques (DCs) chargées de peptides de la protéine topoisomérase I (TOPOIA et TOPOIB). Dans le but de caractériser ce modèle murin et d’établir un profil immunitaire, j’ai concentré mes analyses principalement sur les caractéristiques de la SSc telles que la fibrose, l’inflammation, l’hyper-γ-globulinémie polyclonale, la vasculopathie ainsi que de l’expression de cytokines. Brièvement, l’immunisation de souris avec les DCs chargées avec la topoisomérase I (TOPOI) a induit l’inflammation pulmonaire et cutanée, en plus de la fibrose sous forme diffuse (dcSSc). Les souris présentaient également des symptômes de la vasculopathie ainsi que des taux élevés d’anticorps polyclonaux. Les résultats démontraient que les peptides TOPOIA étaient efficaces dans l’induction de la fibrose et de la réponse inflammatoire alors que les peptides TOPOIB étaient surtout impliqués dans la fibrose cutanée. En plus de nos résultats, les observations préliminaires sur le profil de cytokines tissulaires suggéraient que ce modèle pourrait remplacer ou complémenter les autres modèles animaux de SSc. / Systemic sclerosis (SSc) is a rare disease of unknown etiology that affects people that have a genetic predisposition to autoimmunity. Despite the latest advancement and development in the field, the mechanisms underlying disease development remain poorly understood. The lack of animal model that encompasses the cardinal features of human systemic sclerosis is a major cause of the slowdown in the understanding of this disease. In fact, some mouse models such as the bleomycin induced-SSc and TSK-1 mouse are widely used in preclinical studies of scleroderma. However, these models have several shortcomings since these mice do not display all the cardinal features of the disease found in humans. To contribute to the research of SSc, postdoctoral fellow Dre Heena Mehta has developed in Dre Sarfati’s laboratory in collaboration with Dr Senécal, an experimental murine model of SSc induced by dendritic cells loaded with topoisomerase I peptide. In order to characterise the model and establish an immune profile of our experimental mice, my analysis focused mainly on the cardinal features of scleroderma such as fibrosis, inflammation and polyclonal hyper-γ-globulinemia, vasculopathy and cytokines gene expression. Hence, immunization with dendritic cells loaded topoisomerase I peptides (TOPOIA and TOPOIB) induced pulmonary and dermal inflammation together with diffuse form of fibrosis. The mice also showed symptoms of vasculopathy and high levels of polyclonal antibodies. These results showed that TOPOIA peptides are effective in inducing fibrosis and inflammatory response while TOPOIB peptides are involved in skin fibrosis. Together with the results, the preliminary data on cytokine profile in tissue suggested that our mouse model could possibly replace/complement other current animal models of scleroderma.

No description available.

HTLV-I is the first discovered human retrovirus and a causative agent of both adult T-cell leukemia (ATL) and HTLV-I-associated myelopathy (or tropical spastic paraparesis) (HAM/TSP). Previous models have been successful in providing insight into the progression of HTLV-I infection. The relative simplicity of HTLV as well as its similarities to HIV and other diseases allow HTLV-I research to have diverse applications. The development of HAM/TSP is precipitated by a CTL immune response. Previous models for CTL response to HTLV-I infection have had relatively simple behaviours. A novel sigmoidal CTL response function results in complex behaviours previously unobserved. We establish the existence of bistability between solutions corresponding to carrier and endemic states. In addition, both super- and sub-critical Hopf bifurcations as well as the resulting stable and unstable periodic solutions are observed. Analytical and numerical results are discussed, as well as the biological consequences of the aforementioned behaviours. / Applied Mathematics

No description available.

La polyarthrite rhumatoïde (PR) est la maladie auto-immune la plus fréquente d’une prévalence de 1%. Les cellules résidentes de la cavité synoviale, les fibroblast-like synoviocytes (FLS), sont des acteurs majeurs de la PR. Leur activation par des récepteurs de l’immunité innée participe à l’acquisition d’un phénotype agressif menant à la destruction ostéo-articulaire. Dans cette étude, nous avons évalué le rôle régulateur de miARN sur les voies de signalisation des Toll-like receptors (TLR). L’activation de TLR2 et de TLR4 dans les FLS induit la diminution de l’expression de plusieurs miARN, dont miR-19a et b (miR-19), alors que TLR2 est surexprimé. Nous avons pu ainsi montrer que miR-19 régule Tlr2 et que la transfection de mir-19 dans les FLS activés induit une diminution de l’expression de TLR2 et de la synthèse d’IL-6 et de MMP-3. Mir-19 appartient au cluster miR-17~92, dont l’expression est abaissée dans les FLS. Il code pour 6 miARN dont miR-20a. miR-20a est également sous-régulé après activation de TLR2 et TLR4 dans les FLS et les THP-1. Nous avons montré que miR-20a régule directement l’expression d’Ask1, impliquée et surexprimée après activation de TLR4. La transfection de miR-20a in vitro nous a permis de montrer que miR-20a contrôle l’expression d’ASK1 et induit une inhibition de la synthèse de cytokines majeures de la PR dans les FLS et les THP-1. Des résultats équivalents ont été obtenus ex vivo chez la souris. Ces travaux ont permis d’identifier dans les FLS rhumatoïdes des miARN anti-inflammatoires dont la baisse d’expression permet une augmentation de l’expression de TLR2 et d’ASK1. Ces miARN pourraient donc constituer de nouvelles cibles thérapeutiques. / Rheumatoid arthritis (RA) is the most frequently autoimmune disease with a prevalence of 1%. Resident cells of joints, the fibroblast-like synoviocytes (FLS), act as key players in RA. Their activation through Pattern-recognition receptors leads to an aggressive phenotype, leading in the osteo-articular destruction of the joints. In this study, we aimed to discuss the link between Toll-like receptors (TLR) and miRNA pathway. We established the down-regulation of a few miRNA when FLS were activated through TLR2 and TLR4, including miR-19a and miR-19b (miR-19). We showed that miR-19 regulates directly Tlr2 and that transfection of miR-19 mimics leads to a decrease of IL-6 and MMP-3 synthesis in FLS. miR-19 belongs to the cluster miR-17~92, which is also down-regulated in activated FLS. This primary transcript encodes for 6 miRNA, including miR-20a, which is also down regulated upon TLR2 and TLR4 activation in FLS and further in THP-1, a monocyte cell-line. Then, we validated the predicted regulation of miR-20a on Ask1, an important kinase involved in TLR4 pathway. The transfection of miR-20a mimics in vitro represses ASK1 expression and inhibits several major cytokines in RA both in FLS and THP-1. Further, we confirmed these results on ex vivo experiments on peritoneal macrophages. These works allowed us to identify new anti-inflammatory miRNA that are downregulated and allow overexpression of TLR2 and ASK1 in RA FLS. These results open new experiments on in vivo models. All together, these data give new insights for identify new therapeutics in RA.

Introduction:Uveitis in an ocular inflammation affecting mostly people of working age. Uveitis is responsible for severe visual impairment despite of expanding new therapeutics. The animal models of uveitis were established, because the wide clinical variability of uveitis limits the studies in human medicine. The goal our project was to establish a reproducible model of experimental autoimmune uveitis in Czech Republic, and further on this model to observe the frequency of CD3+ and F4/80+ cells in retina, to assess the influence of microbial environment on intensity of intraocular inflammation and to test the therapeutical possibilities. Material and methods: The C57BL/6J mice were immunized by retinal antigen (IRBP 1-20, interphotoreceptor retinoid binding protein), enhanced by complete Freund's adjuvant and pertussis toxin and mild posterior autoimmune uveitis was induced. The mice were bred in conventional and germ-free (gnotobiotic) conditions. The uveitis intensity was evaluated in vivo biomicroscopically and post mortem histologically on hematoxylin eosin stained sections according to the standard protocol. The histological eye specimen were analyzed also by imunohistochemisty and by flow cytometry. Each experiment was performed for 35 days. The conventional mice with uveitis were treated...

Introduction:Uveitis in an ocular inflammation affecting mostly people of working age. Uveitis is responsible for severe visual impairment despite of expanding new therapeutics. The animal models of uveitis were established, because the wide clinical variability of uveitis limits the studies in human medicine. The goal our project was to establish a reproducible model of experimental autoimmune uveitis in Czech Republic, and further on this model to observe the frequency of CD3+ and F4/80+ cells in retina, to assess the influence of microbial environment on intensity of intraocular inflammation and to test the therapeutical possibilities. Material and methods: The C57BL/6J mice were immunized by retinal antigen (IRBP 1-20, interphotoreceptor retinoid binding protein), enhanced by complete Freund's adjuvant and pertussis toxin and mild posterior autoimmune uveitis was induced. The mice were bred in conventional and germ-free (gnotobiotic) conditions. The uveitis intensity was evaluated in vivo biomicroscopically and post mortem histologically on hematoxylin eosin stained sections according to the standard protocol. The histological eye specimen were analyzed also by imunohistochemisty and by flow cytometry. Each experiment was performed for 35 days. The conventional mice with uveitis were treated...

Objectives: The management of patients with multifocal motor neuropathy (MMN) under everyday clinical conditions has been insufficiently studied. We therefore collected comprehensive observational data on patients with MMN who received intravenous (IV) or subcutaneous (SC) immunoglobulins (IGs) as maintenance therapy. Methods: This was a prospective, noninterventional study (registry) in neurological centres (hospitals and offices) throughout Germany. Results: As of 1 December 2015, 80 patients with MMN were included (mean age 55.4 ± 9.8 years, 67% males, mean disease duration 10.7 ± 10.2 years). The affected limb regions were predominantly distal muscle groups of the upper extremities. On the inflammatory neuropathy cause and treatment (INCAT) scale, 94% of the patients had some disability in the arms and 61% in the legs. At inclusion, 98.8% received IVIG and 1.3% SCIG. Substantial variation was observed between IVIG treatment intervals (every 0.7 to 17.3 weeks) and dosage (0.2–2.1 g/kg body weight received during a single administration; mean monthly dosage, 0.9 g/kg body weight). However, the mean monthly dosage was steady over time. At 1-year follow up, improvement was seen in muscle strength, INCAT and quality of life (QoL) scores (SF-36 questionnaire). Conclusions: The management of patients with MMN in everyday clinical practice demonstrates a wide range of absolute dosages and treatment intervals of IG, supporting the recommended practice of determining treatment dose on an individual patient basis. The improvements in muscle strength and reduction in disability, accompanied by increased QoL, strengthen the case for use of IG as a maintenance treatment for MMN.

Introduktion: Fetal microchimerism är en fysiologisk process som sker under en graviditet, och innebär att ett lågt antal av intakta fosterceller överförs från fostrets blodcirkulation till moderns blodcirkulation via placentan. Fetala celler kan sedan detekteras i moderns cirkulation samt i moderns vävnader i upp till 27 år efter förlossningen. De överförda fetala cellerna ger upphov till livslånga fysiologiska konsekvenser hos modern vad gäller utveckling, hälsa och sjukdom. Syfte: Examenarbetets syfte var att med hjälp av kliniska studier undersöka fördelaktiga och skadliga effekter av fetal microchimerism på moderns fysiologi. Metod: Arbetet är en litteraturstudie baserad på fem kliniska studier sökta från databasen PubMed. Studierna granskades kritiskt tillsammans med andra relevanta artiklar inom ämnetför att besvara litteraturstudiens syfte. Resultat: Studien visade att fetal microchimerism är en process som påverkar moderns fysiologi på både ett fördelaktigt och skadligt vis. Fetal microchimerism ökar risken för uppkomst av autoimmuna sjukdomar, och minskar risken för uppkomst av äggstockscancer, ischemisk hjärtsjukdom samt virussjukdomen Covid-19. Vidare är fetal microchimerism positivt bidragande i fysiologiska processer som sårläkning. Sammantaget visar litteraturstudien att de fördelaktiga processerna av fetal microchimerism är fler än de skadliga, och att immunologiska faktorer spelar en viktig roll. Slutsats: Genom litteraturstudien kan konstateras att fetal microchimerism påverkar moderns fysiologi i flertalet fysiologiska processer, vilket bidrar till att fetal microchimerism kan ses som djupgående och avgörande för moderns hälso- och sjukdomsstatus. / Introduction: Fetal microchimerism is a physiological process during pregnancy and means that a low levels of fetal cells are transmitted from fetal blood circulation to mothers’ blood circulation via the placenta. Fetal cells can then be detected in the mother´s circulation and tissues for up to 27 years after delivery. The transferred fetal cells give rise to lifelong physiological consequences in the mother’s development, health and disease. Aim: The aim of the study was to investigate beneficial and harmful effects of fetal microchimerism on mother´s physiology. Method: This work is a literature review based on five clinical studies from the PubMeddatabase. The studies and other relevant articles on the subject were critically reviewed to answer the purpose of the literature study.  Results: The study showed that fetal microchimerism is a process that affects mother´s physiology both beneficially and harmfully. Fetal microchimerism contributes to the emergence of autoimmune diseases in a negative way and reduces the risk to the emergence of ovarian cancer, ischemic heart disease and Covid-19 in a positive way. Fetal microchimerism is also positively contributing to physiological processes such as wound healing. Overall, the literature study shows that the beneficial effects of fetal microchimerism are more than the harmful andthat immunological factors play an essential role. Conclusion: The study found that fetal microchimerism affects the mother´s physiology in many physical processes, which means that fetal microchimerism is profound and decisive in mother´s health.

Ungefähr 1% der Bevölkerung der westlichen Welt leidet an rheumatoider Arthritis (RA). In einem T-Zellrezeptor transgenen Mausmodell, dem K/BxN Modell, wird die ubiquitär exprimierte Glukose-6-phosphat Isomerase (G6PI) von autoreaktiven T- und B-Zellen erkannt. Diese Mäuse entwickeln spontan eine antikörpervermittelte Arthritis, die viele Gemeinsamkeiten mit der humanen RA aufweist. In dieser Arbeit wurde untersucht, ob die Immunisierung mit G6PI eine Arthritis auch in nicht-transgenen Mäuse induzieren kann. Die Immunisierung mit heterologer humaner G6PI führte zur Entwicklung einer peripheren symmetrischen Polyarthritis in über 95% der DBA/1 Mäuse. Damit konnte zum ersten Mal gezeigt werden, dass eine Immunreaktion gegen ein systemisches exprimiertes Antigen zur einer organspezifischen Erkrankung in normalen nicht-transgenen Mäusen führt. Die Tiere entwickeln nach 9 Tagen eine Arthritis, die bis Tag 15 ihr Maximum erreicht hat und dann langsam abnimmt. Histologisch ist die Arthritis durch eine frühe Synovitis charakterisiert, gefolgt von massiven Erosionen des Knorpel und Knochens und anschließenden Reparaturprozessen, inklusive Fibrose. Obwohl die Tiere hohe Antikörpertiter entwickeln, kann die Arthritis nicht durch aufgereinigte Antikörper kranker Mäuse transferiert werden. Trotzdem spielen Antikörper eine große Rolle, da FcR-gamma-Kette defiziente Mäuse eine Arthritis mit geringer Inzidenz und mildem Verlauf entwickeln. Die Depletion der CD4 positiven Zellen verhindert die Entwicklung der Arthritis völlig, und eine Depletion während der Erkrankung führt zur schnellen Heilung. Daneben ist für die Entwicklung der Arthritis auch das Komplementsystem und TNF-alpha entscheidend, was durch Depletion von C5 bzw. durch Blockade von TNF-alpha gezeigt wurde. Zusätzlich wurde die Rolle der G6PI bei der Pathogenese der RA im Menschen untersucht. RA-Patienten zeigten keine erhöhte Frequenz von CD4 positiven T-Zellen, die nach Restimulation mit G6PI TNF-alpha oder IFN-gamma produzierten. Außerdem konnten keine erhöhten anti-G6PI Titer in Patienten mit RA oder anderen rheumatischen Erkrankungen detektiert werden. / About 1% of the of the population of the western world suffers from rheumatoid arthritis (RA). In a T-cell receptor transgenic mouse model, the K/BxN model, the ubiquitously expressed glucose-6-phosphate isomerase (G6PI) is recognized by autoreactive T- and B-cells. These mice do develop an antibody dependent arthritis which show a lot of features of human RA. In this study it was examined whether arthritis could be induced in normal non-transgenic mice by immunization with G6PI. Immunization with heterologous human G6PI induces a symmetric polyarthritis in over 95% of DBA/1 mice. Therewith showing for the first time that an immune reaction against an systemic expressed antigen will lead to the development of an organ specific disease in normal non-transgenic mice. The mice develop arthritis 9d after immunization, reach their maximum at d15 and then arthritis slowly resolve. Histologically, the disease is characterized by early synovitis followed by massive cartilage destruction and erosions of the bones and later repair processes including fibrosis. Although antibody titers in the mice are high, transfer of purified anti-G6PI antibodies of sick mice alone do not transfer disease. Anyway, antibodies seem to play a major role since FcR-gamma-chain deficient mice develop disease with a much lower frequency and reduced severity. Depletion of CD4 positive T cells completely prevents disease and depletion during disease leads to an rapid resolution of arthritis. Aside this, complement and TNF-alpha is critical for the development of arthritis, which could shown by depletion of C5 and blockade of TNF-alpha. In addition, the role of G6PI in the pathogenesis of RA in humans was examined. RA patients do not show a higher frequency of CD4 positive T-cells which produce TNF-alpha and IFN-gamma after restimulation with G6PI. Furthermore, no elevated anti-G6PI titers could be detected in RA patients and in patients with other rheumatic diseases.